CalciMedica, Inc. (NASDAQ:CALC) Sees Large Increase in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 72,600 shares, an increase of 112.3% from the October 15th total of 34,200 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average daily volume of 52,900 shares, the short-interest ratio is currently 1.4 days.

CalciMedica Stock Down 1.2 %

Shares of CALC traded down $0.04 during mid-day trading on Friday, reaching $3.33. 69,828 shares of the stock traded hands, compared to its average volume of 36,805. The stock has a fifty day simple moving average of $4.04 and a 200 day simple moving average of $4.54. CalciMedica has a 12-month low of $2.68 and a 12-month high of $8.38. The firm has a market cap of $35.80 million, a price-to-earnings ratio of -3.08 and a beta of 1.30.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities research analysts expect that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research note on Thursday.

Insiders Place Their Bets

In other news, CEO A. Rachel Leheny acquired 20,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now directly owns 130,926 shares in the company, valued at $490,972.50. This trade represents a 18.03 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of CalciMedica stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, for a total transaction of $325,751.25. Following the completion of the purchase, the insider now directly owns 814,300 shares in the company, valued at approximately $3,053,625. This represents a 11.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 312,944 shares of company stock valued at $1,172,910 over the last quarter. Company insiders own 41.55% of the company’s stock.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc raised its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.